Summit Therapeutics Inc (NASDAQ:SMMT) price on Wednesday, April 30, rose 2.12% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $24.12.
A look at the stock’s price movement, the close in the last trading session was $23.62, moving within a range at $22.84 and $24.35. The beta value (5-Year monthly) was -0.46. Turning to its 52-week performance, $36.91 and $2.10 were the 52-week high and 52-week low respectively. Overall, SMMT moved 25.04% over the past month.
Summit Therapeutics Inc’s market cap currently stands at around $17.79 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-23.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SMMT is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend SMMT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SMMT’s current price about 2.96% and 13.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.04, while 7-day volatility ratio is 20.95% and 14.54% in the 30-day chart. Further, Summit Therapeutics Inc (SMMT) has a beta value of -0.94, and an average true range (ATR) of 3.18. Analysts have given the company’s stock an average 52-week price target of $35, forecast between a low of $30 and high of $44. Looking at the price targets, the low is -24.38% off current price level while to achieve the yearly target high, price needs to move -82.42%. Nonetheless, investors will most likely welcome a -45.11% jump to $35 which is the analysts’ median price.
If we refocus on Summit Therapeutics Inc (NASDAQ:SMMT), historical trading data shows that trading volumes averaged 8.09 over the past 10 days and 3.75 million over the past 3 months. The company’s latest data on shares outstanding shows there are 737.63 million shares.
The 84.93% of Summit Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 12.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 25.09 million on 2025-04-15, giving us a short ratio of 7.15. The data shows that as of 2025-04-15 short interest in Summit Therapeutics Inc (SMMT) stood at 2107.9999000000003 of shares outstanding, with shares short rising to 21.22 million registered in 2025-03-14. Current price change has pushed the stock 35.16% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SMMT stock continues to rise going into the next quarter.
